Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan vs. FDA (And Ranbaxy): Diovan Exclusivity Forfeiture Edition

This article was originally published in The Pink Sheet Daily

Executive Summary

In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.

Advertisement

Related Content

Ranbaxy’s Valsartan ANDA Wins FDA Approval After Lengthy Delay
Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete
Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete
Status Of Ranbaxy’s First Filer Status For Dioxan Remains A Mystery After Judge Tosses Mylan Lawsuit
Diovan Generic Exclusivity Mystery Deepens After Judge Tosses Mylan Lawsuit
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
Watson’s Generic Lidoderm Approval Leaves Questions About Exclusivity
No Need To Fight: Teva Retains Provigil Generic Exclusivity Even Without “Adversarial” Relationship
Teva’s Generic Irbesartan Deserves 180-Day Exclusivity Because Of Review Delays, FDA Says
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel